Product Reports Resources Pricing Login Book a demo

RA Capital Management

Venture Capital · Founded 2001 · Boston, United States

#176 Investor Ranking 2026 Top 1% of investors worldwide

We are dedicated to evidence-based investing in public and private healthcare and life science companies developing drugs, medical devices, diagnostics, services, and research tools

315 Portfolio companies+60% in 5 years
83 Unicorns
9 Decacorns
502 Investments
Aug 2026 Last investment
02 · Biggest holdings

RA Capital Management’s biggest current holdings.

The most valuable companies RA Capital Management still holds, ordered by Dealroom’s latest valuation. Companies that have been acquired or gone public are in Exits instead. Dealroom has no parsed shareholder register for RA Capital Management, so the size of each stake isn’t shown.

#CompanyValuation
  1. 1 Intarcia TherapeuticsUnicorn · Health · USA $3.9B
  2. 2 SomatusUnicorn · Health · USA $2.5B
  3. 3 Stipple BioUnicorn · Health · USA $2.2B
  4. 4 Verdiva BioUnicorn · Health · UK $2.0B

Unicorns and thoroughbreds RA Capital Management has backed and still holds, at Dealroom’s latest valuation. See the underlying shareholder registers on Dealroom →

03 · Exits

RA Capital Management’s biggest exits.

Portfolio companies that IPO’d or were acquired at $1B+, with the valuation recorded at exit and — for those still public — their value today. Exit events come from each company’s funding-round history; entry stage from RA Capital Management’s transaction record.

$1.8B IPO · 2015
Entered Series B+Now $46BHealth
$7.5B IPO · 2018
Entered Series B+Now $20BHealth
$373M IPO · 2015
Entered Series B+Now $17BHealth
$457M IPO · 2019
Entered Series B+Now $13BHealth
IPO · 2020
Now $12BHealth
IPO · 2004
Now $12BHealth
$163M IPO · 2017
Now $10BHealth
$320M IPO · 2015
Entered Series B+Now $9.2BHealth
$809M IPO · 2023
Entered Series B+Now $9.2BHealth
$90M IPO · 2016
Entered Series B+Now $8.7BHealth
$398M IPO · 2015
Entered Series B+Now $8.3BHealth
$130M IPO · 2016
Now $8.1BHealth
04 · Portfolio analysis

Where RA Capital Management’s portfolio is concentrated.

Distribution of portfolio companies by headquarters country, sector, entry stage and current growth stage. Across all 315 portfolio companies. "Stage entered" is the first priced round the investor joined, derived from the investor’s transaction history.

By countryCount
  1. USA309
  2. UK13
  3. Canada7
  4. Denmark7
  5. China5
  6. Switzerland4
  7. Germany3
  8. Ireland3
  9. Israel3
  10. Netherlands3
  11. Belgium2
  12. France2
By sectorCount
  1. Health355
  2. Food6
  3. Energy4
  4. Robotics3
  5. Transportation3
  6. Kids2
  7. Enterprise Software1
  8. Media1
  9. Sports1
By stage enteredCount
  1. Series B+192
  2. Series A76
  3. Seed15
By growth stageCount
  1. Late Growth271
  2. Breakout Stage78
  3. Early Growth14
  4. Mature5
05 · Portfolio market map

Inside RA Capital Management’s portfolio.

The 60 highest-funded portfolio companies, of 315 tracked.

Moderna Therapeutics
Health · Decacorn
$20B
Johnson & Johnson Innovative Medicine
Health
Intarcia Therapeutics
Health · Unicorn
$3.9B
Freenome
Health · Unicorn
$1.3B
Element Biosciences
Health · Unicorn
$1.4B
Parabilis Medicines
Health · Unicorn
$4.8B
Bicycle Therapeutics
Health
Obsidian Therapeutics
Health
$642M
Cerevel Therapeutics
Health · Unicorn
$6.9B
Nimbus Therapeutics
Health
$840M
Century Therapeutics
Health
$272M
Avidity Biosciences
Health · Decacorn
$12B
Cidara Therapeutics
Health · Unicorn
$9.2B
Metsera
Health · Unicorn
$4.9B
Solid Biosciences
Health
$541M
Somatus
Health · Unicorn
$2.5B
CellCentric
Health
$880M
Olema Oncology
Health
$550M
Invivyd
Health · Unicorn
$1.8B
Arvinas
Health
$12M
Crinetics Pharmaceuticals
Health · Unicorn
$7.8B
Synthego
Health
$800M
CORXEL Pharmaceuticals
Health · Unicorn
$1.1B
Surrozen
Health
$205M
Galecto | Damora Therapeutics
Health · Unicorn
$1.9B
Ollin Biosciences
Health · Unicorn
$1.3B
Verdiva Bio
Health · Unicorn
$2.0B
NewAmsterdam Pharma
Health · Unicorn
$2.7B
Abcuro
Health
$800M
SAB Biotherapeutics
Health
$257M
COMPASS Pathways
Health · Unicorn
$1.4B
Artios Pharma
Health
$765M
Metagenomi
Health
Carmot Therapeutics
Health · Unicorn
$2.7B
Vividion Therapeutics
Health · Unicorn
$1.5B
Ventus Therapeutics
Health
$280M
Angitia Biopharmaceuticals
Health
$520M
Alentis Therapeutics
Health
$900M
Windward Bio
Health
$825M
Day One Biopharmaceuticals
Health · Unicorn
$1.8B
Verve Therapeutics
Health
$566M
Everest Medicines
Health
$898M
Terremoto Biosciences
Health
$875M
Be Bio
Health
$650M
Tyra Biosciences
Health · Unicorn
$1.2B
Dianthus Therapeutics
Health · Unicorn
$5.2B
Tango Therapeutics
Health · Unicorn
$4.1B
Hemab Therapeutics
Health · Unicorn
$2.2B
Capstan Therapeutics
Health · Unicorn
$2.1B
Pyxis Oncology
Health
$214M
Aktis Oncology
Health
$807M
AltruBio
Health
$900M
ViaCyte
Health
$320M
ADCendo
Health
$712M
CG Oncology
Health · Unicorn
$5.6B
Star Therapeutics
Health
$500M
Bicara Therapeutics
Health · Unicorn
$1.3B
LianBio
Health
Orchard Therapeutics
Health
$303M
Exo
Health
$880M
06 · Portfolio founders

Where RA Capital Management’s portfolio founders come from.

175 founders across the 100 highest-funded portfolio companies — by current location, university attended, and the companies they worked at before founding. Sourced from the founder records the API links to each portfolio company.

LocationCount
  1. United States135
  2. United Kingdom13
  3. Denmark10
  4. Switzerland5
  5. Australia2
  6. China2
  7. Netherlands2
  8. Chile1
  9. France1
  10. Sweden1
UniversityCount
  1. Massachusetts Institute of Technology12
  2. Harvard University11
  3. Harvard Medical School7
  4. Stanford University7
  5. University of California, Berkeley7
  6. University of Copenhagen4
  7. Dartmouth College3
  8. ETH Zurich3
  9. Stanford University School of Medicine3
  10. The University of Chicago3
Previous companyCount
  1. Harvard Medical School6
  2. Dana-Farber Cancer Institute5
  3. Genentech5
  4. McKinsey & Company5
  5. Novartis5
  6. Roche5
  7. Broad Institute4
  8. Sanofi Aventis4
  9. Amblyotech3
  10. GSK3